LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Inicio・Lista de Acciones・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Abierto

SectorSalud

1.09 2.83

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.05

Máximo

1.08

Métricas clave
By Trading Economics
Ingresos	29M 3.3M
Ventas	28M 29M
Margen de beneficio	11.266
Empleados	103
EBITDA	31M 5.7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+154.63% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-7M 400M
Apertura anterior	-1.74
Cierre anterior	1.09

Noticias sobre sentimiento de mercado

By Acuity

50%

173 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

0.6863 / 0.72 Soporte y Resistencia

Lexicon Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 12:42 UTC

Principales Movimientos del Mercado

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Comparación entre iguales

Cambio de precio

Lexicon Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

154.63% repunte

Estimación a 12 meses

Media 2.75 USD 154.63%

Máximo 6 USD

Mínimo 0.85 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6863 / 0.72Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentimiento

By Acuity

173 / 371 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.